National Cancer Center Hospital East

This study tested a combination of three drugs—regorafenib, nivolumab, and chemotherapy—in 30 people with advanced or recurrent stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery. The goal was to see if the combination was safe and effec…

This study tested whether a chemotherapy drug called FTD/TPI can prevent colorectal cancer from coming back in patients who had surgery to remove their tumors but still have cancer DNA in their blood. 243 patients were randomly assigned to receive either the drug or a placebo. Th…

This study tested a drug called darolutamide, usually used for prostate cancer, in 57 people with a rare type of salivary gland cancer that has a specific protein (androgen receptor). The goal was to see if the drug could shrink tumors or slow the cancer's growth. Some participan…

This study tested a combination of three drugs—trastuzumab deruxtecan (a targeted therapy), nivolumab (an immunotherapy), and chemotherapy—in 30 people with advanced HER2-low stomach or gastroesophageal junction cancer who had not received prior treatment. The goal was to find th…